Supplemental material
Expert Opinion on Biological Therapy
Volume 23, 2023 - Issue 8: Biosimilars
Original Research
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey
Patrícia Sarlósa Department of Medicine, University of Pecs Medical School, Pecs, Hungary;b Institute for Translational Medicine, University of Pecs Medical School, Pecs, HungaryCorrespondence[email protected]
https://orcid.org/0000-0002-5086-9455
https://orcid.org/0000-0002-5086-9455, Alexander Bikara Department of Medicine, University of Pecs Medical School, Pecs, Hungaryhttps://orcid.org/0009-0004-2225-2193
https://orcid.org/0009-0004-2225-2193, , , Zoltán Szepesc Department of Medicine, University of Szeged Albert Szent-Györgyi, Szeged, Hungaryhttps://orcid.org/0000-0002-9466-8719
https://orcid.org/0000-0002-9466-8719, Klaudia Farkasc Department of Medicine, University of Szeged Albert Szent-Györgyi, Szeged, Hungaryhttps://orcid.org/0000-0003-0599-182X
https://orcid.org/0000-0003-0599-182X, , , & Tamás Molnárc Department of Medicine, University of Szeged Albert Szent-Györgyi, Szeged, Hungaryhttps://orcid.org/0000-0002-4913-7599
https://orcid.org/0000-0002-4913-7599 show all